An epithelial-mesenchymal transition (EMT) underlies malignant tumor progression and metastatic spread by enabling cancer cells to depart from the primary tumor, invade surrounding tissue, and disseminate to distant organs. EMT also enriches for cancer stem cells (CSC) and increases the capacity of cancer cells to initiate and propagate tumors upon transplantation into immune-deficient mice, a major hallmark of CSCs. However, the molecular mechanisms promoting the tumorigenicity of cancer cells undergoing an EMT and of CSCs have remained widely elusive. We here report that EMT confers efficient tumorigenicity to murine breast cancer cells by the upregulated expression of the proangiogenic factor VEGF-A and by increased tumor angiogenesis. On the basis of these data, we propose a novel interpretation of the features of CSCs with EMT-induced, VEGF-Amediated angiogenesis as the connecting mechanism between cancer cell stemness and tumor initiation. Cancer Res; 74(5); 1566-75. Ó2014 AACR.
Introduction
A key feature of progressive solid tumors is the acquisition of the potential to invade neighboring tissue and to disseminate throughout the body and form metastatic lesions at distant sites (1) (2) (3) . Tumor cells achieve this by activating an epithelialmesenchymal transition (EMT) program to undergo phenotypic changes, such as the loss of cell-cell adhesion and the gain of cell migration capabilities to evade from the primary tumor. The tissue remodeling processes occurring during EMT are shared by embryonic development, wound healing, and metastasis formation. Molecular hallmarks of EMT are the loss of cell polarity, the loss of epithelial markers, such as E-cadherin and ZO-1, the gain of the expression of mesenchymal markers, such as N-cadherin, vimentin, and fibronectin, a dramatic cytoskeletal reorganization accompanied by the change from an epithelial, differentiated morphology to a fibroblast-like, motile, and invasive cell behavior (3) (4) (5) . Among many growth factors, TGF-b is one of the most potent inducers of EMT.
Interestingly, besides promoting invasiveness, TGFb-induced EMT has been shown to induce the transition of transformed and immortalized human mammary epithelial cells into mesenchymal cancer cells with stem cell traits, thus linking EMT to tumor cell plasticity. In fact, EMT enriches for cancer stem cells (CSC) and increases tumorigenic potential of cancer cells upon transplantation into immunodeficient mice (6, 7) . The ultimate hallmark of CSCs and metastatic cells is their ability to initiate tumors de novo (8) . CSCs promote tumor growth through their ability to self-renew and to differentiate. However, the molecular mechanisms promoting the tumorigenicity of cancer cells undergoing an EMT have remained widely elusive. Here, we report that EMT confers increased tumorigenicity to murine breast cancer cells by the upregulated expression of VEGF-A and by increased tumor angiogenesis. Notably, VEGF-A expression is required for the increased tumor initiation capacity of breast cancer cells that have undergone EMT. However, VEGF-A by itself is not sufficient to fully support tumor formation of epithelial breast cancer cells before EMT, indicating that additional factors induced during EMT contribute to efficient tumor initiation. We propose a novel interpretation of the features of CSCs with EMT-induced, VEGF-Amediated angiogenesis as the connecting mechanism between cancer cell stemness and tumor initiation.
Materials and Methods
For details, see Supplementary Data.
Cell lines and reagents
A subclone of normal murine mammary gland epithelial (NMuMG) cells (NMuMG/E9; hereafter NMuMG) expressing E-cadherin has been described earlier (26) . MTflECad and MTDECad cells have been previously described (9) . Py2T cells were established from an MMTV-PyMT mammary gland tumor (10) . All these cells have been derived or propagated in house for years and tested for mouse epithelial marker expression by reverse transcriptase (RT)-PCR and immunofluorescence stainings. MDA-MB-231 cells were a kind gift of N. Hynes (Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland) and were tested for human breast cancer markers by RT-PCR and immunofluorescence stainings. All cells were cultured in Dulbecco's Modified Eagle Medium supplemented with glutamine, penicillin, streptomycin, and 10% fetal calf serum (Sigma-Aldrich).
Orthotopic transplantation
Two-dimensional (2D) cultured cells or second passage mammospheres (M2) were injected as a single-cell suspension in PBS at defined cell numbers into the ninth mammary gland of 7 to 10-week-old females BALB/c Rag2 À/À ;common g receptor À/À (RG mice; a kind gift from A. Rolink, University of Basel, Basel, Switzerland).
Lung metastasis and trap assay MMTV-Neu mice were injected intravenously with 10 6
MTflECad and MTDECad cells resuspended in PBS. Three weeks or 3 days after injections, respectively, mice were sacrificed and lung metastases or GFP-positive cancer cells trapped in the lung were scored. All experimental procedures involving mice were performed according to the guidelines of the Swiss Federal Veterinary Office (SFVO) and the regulations of the Cantonal Veterinary Office of Basel Stadt (licences 1878, 1907, 1908) .
Immunofluorescence microscopy
Cryostat and paraffin sections were prepared as described previously (9) . Seven micrometer cryostat sections of tumor samples were permeabilized with 0.1% Triton-X100 PBS, blocked with 5% goat serum or bovine serum albumin for 1 hour at room temperature, stained overnight at 4 C with primary antibodies against CD31 (1:50; 440274, BD Pharmingen), NG2 (1:100, AB5320 Millipore) followed by fluorescent secondary antibodies (Alexa Fluor; Invitrogen). Nuclei were counterstained with 4 0 , 6-diamidino-2-phenylindole (DAPI). To assess tissue hypoxia, mice were injected intraperitoneally with 60 mg/kg hypoxyprobe for 30 minutes before sacrifice and cryostat sections were processed according to the protocol (Hypoxyprobe-1 Kit, HPI). Immunofluorescence pictures were acquired with a Leica DMI 4000. ImageJ was used for processing and analysis of the signal intensity.
Mammospheres were fixed in 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 and stained overnight with antibodies against N-cadherin (33-3900 Zymed) and E-cadherin (13-1900 Zymed) . Py2T cells were incubated with 5(6)-carboxyfluorescein N-hydroxysuccinimidyl ester (CFSE; 0.1 mmol/L) before spheroid culturing and unfixed spheroids were stained for living and dead cells with Hoechst and propidium iodide. Confocal sequential images were acquired using a Leica SP5 confocal microscope and three-dimensional (3D) images were generated using IMARIS software.
Statistical analysis
The statistical significance between the tumor onset of two groups of mice was either tested by the Mann-Whitney U test or Fisher exact test in cases in which mice did not develop any tumors. For all further animal experiments, statistical significance was determined by the Mann-Whitney U test if not (13), the CSC surface markers CD24, CD29, and CD49f (14) failed to identify subpopulations of cells that were increased during EMT in the three murine cellular systems (Supplementary Table S1 ).
We next assessed the tumorigenic potential of epithelial MTflECad and mesenchymal MTDECad cells by orthotopic transplantation into the mammary fat pad of immunodeficient BALB/c Rag2 implantation (3D/M2), these differences became even more apparent (Fig. 2B) . Upon spheroid selection, as few as 10 MTDECad cells were able to efficiently initiate a tumor, whereas 10 MTflECad cells failed to do so. Epithelial MTflECad cells gave rise to tumors with epithelial morphology, defined borders, and central necrotic areas, whereas tumors formed by MTDECad cells showed an invasive, fibroblast-like appearance in the absence of necrosis (Fig. 2C) . Consistent with their increased tumorigenicity, mesenchymal MTDECad cells also formed more and larger lung metastases than epithelial MTflECad cells following orthotopic transplantation into RG mice (Fig. 3A-C) . Upon tail vein injection into syngeneic MMTV-Neu transgenic mice, epithelial MTflECad cells seeded many small lung metastases, whereas mesenchymal MTDECad cells initiated less but larger lung metastases ( Fig. 3D and E) . No difference was observed in the ability of the cells to home to the lungs upon injection into the tail vein ( Supplementary Fig. S2A ), suggesting that the difference in metastatic outgrowth was due to tumor growth parameters at the distant site.
Both primary and metastatic MTDECad tumors exhibited significantly higher microvessel densities and reduced levels of apoptosis yet unchanged proliferation as compared with MTflECad tumors and metastases (Fig. 4A-D and Supplementary Fig. S2B and S2C ). MTDECad tumors also displayed higher levels of VEGF receptor 2 and 3 expression in their vasculature as compared with MTflECad tumors (Supplementary Fig. S3A ), indicating an activation of tumor angiogenesis. Lectin perfusion and pericyte coverage experiments showed that the vessels within the tumors and metastases were all functional A, RG mice transplanted as described in Fig. 2 and that MTDECad tumors displays more perfused vessels than the MTflECad ones ( Supplementary Fig. S3B-S3D ). In contrast to mesenchymal MTDECad tumors, epithelial MTflECad tumors also exhibited large hypoxic and necrotic areas associated with high levels of apoptosis yet unchanged proliferation ( Fig. 4E and Supplementary Fig. S3E and S3F ). Consistent with these findings, in a transgenic mouse model of pancreatic b-cell carcinogenesis (Rip1Tag2, RT2; ref. 15) loss of E-cadherin in the tumor cells (RT2;b-DECad) not only correlated with increased tumor invasion and metastasis but also with intensified tumor angiogenesis (Fig. 4F and data not  shown) . Conversely, the genetic depletion of the transcriptional repressor of E-cadherin expression Snail-1 in Rip1Tag2 mice (RT2;b-DSnai1) resulted in reduced tumor invasion and tumor microvessel densities (Fig. 4F and data not shown) . These results indicate a strong correlation between EMT and tumor angiogenesis. Gene expression profiling of MTflECad, Py2T, and NMuMG cells before and after EMT revealed that, in addition to the activation of genes involved in cellular differentiation, cell motility, and adhesion, EMT also induced the expression of genes involved in the regulation of angiogenesis, including the gene encoding the proangiogenic factor VEGF-A (Supplementary Fig. S4A and S4B) . A transient increase of VEGF-A levels by TGF-b has been previously reported in the absence of an EMT (16), yet in our in vitro models, increased VEGF-A expression is associated with the induction of an EMT. The increased angiogenesis observed in tumors formed by MTDECad cells correlated with high VEGF-A protein and mRNA levels in cultured MTDECad cells (Fig. 5A and B) . Spheroid culturing caused a further increase in VEGF-A levels (Fig. 5B ) Notably, cultured MTflECad cells expressed low amounts of VEGF-A compared with the MTDECad cells. In contrast, high VEGF-A protein levels were found in large MTflECad tumors (Fig. 5C ), most likely due to the tumor hypoxia and necrosis observed in these tumors (Fig. 2C) . We conclude that MTDECad cells exhibit high VEGF-A levels already when implanted into mice, while MTflECad with low levels of VEGF-A expression cells need to undergo an angiogenic switch for efficient tumor outgrowth. Supporting this notion, MTDECad tumors smaller than 2 mm in diameter were highly vascularized, whereas small MTflECad tumors widely lacked intratumoral microvessels (Fig. 5D) .
To assess the functional contribution of VEGF-A to tumor initiation, we generated MTflECad and MTDECad cells that stably expressed shRNA against VEGF-A (shVA) or a nontargeting control shRNA (shCtr; Fig. 6A and Supplementary Fig.  S5A ). Upon EMT, silencing of VEGF-A significantly impaired tumor onset: 200 MTDECad shCtr cells gave rise to tumors after 30 days, whereas no tumors were palpable at this time in mice transplanted with 200 MTDECad shVA#1 or MTflECad shCtr cells (Fig. 6B) . Depletion of VEGF-A in epithelial MTflECad shVA #1 cells only moderately delayed tumor onset as compared with MTflECad shCtr cells. Independent experiments employing additional shRNA sequences against VEGF-A confirmed the reliance of early tumor onset on VEGF-A expression (Fig. 6C and D and Supplementary Fig.  S5B ). Consistent with their reduced expression of VEGF-A, MTDECad shVEGF-A tumors exhibited significantly reduced (green) and DAPI (blue). Scale bars, 100 mm. B and C, CD31-positive counts per area (B) and the area fraction (C) of CD31 staining were quantified using ImageJ software. N ¼ 6 mice per group. Statistical significance was calculated using a Mann-Whitney U test. ÃÃ , P < 0.01; ÃÃÃ , P < 0.001. D, histologic sections of lung metastases formed after intravenous injection of MTflECad and MTDECad cells into the tail veins of syngeneic MMTV-Neu mice were stained for CD31 (brown) and with hematoxylin (purple). Representative light microscopy pictures are shown. Scale bars, 100 mm. E, hypoxia in MTflECad and MTDECad tumors was visualized by injecting pimonidazole into mice before sacrifice and immunofluorescence staining for its adducts (green), CD31 (red), and DAPI (blue). Representative immunofluorescence microscopy pictures are shown. Scale bars, 100 mm. F, quantification of microvessel density by immunofluorescence staining for CD31 on histologic sections from control Rip1Tag2 (RT2) tumors and Rip1Tag2 tumors with a b-cell-specific Cdh1 knockout (RT2; bDECad) or Rip1Tag2 tumors with a b-cell-specific Snai1 knockout (RT2;bDSnai1). Shown is the area fraction of CD31 þ staining. One data point represents one mouse with at least three microscopic fields analyzed. (Fig. 6E-G) . Orthotopic implantation of 10 spheroid-cultured, VEGF-A-depleted MTDECad cells (shVA #1, #4, #5, #8) failed to provoke the efficient tumor formation observed with 10 MTDECad shCtr cells, further underscoring the critical requirement of VEGF-A for the increased tumor initiation of the cells after an EMT (Fig.  6H) . Depletion of VEGF-A did neither significantly affect MTflECad and MTDECad cell proliferation nor mammosphere formation ( Supplementary Fig. S5C-S5E ), indicating that VEGF-A did not directly affect tumor cell proliferation and survival or cancer stemness. Finally, treatment of mice transplanted with MTflECad or MTDECad cells with the VEGF receptor inhibitor PTK787/ZK222584 (PTK) significantly impaired vascularization and growth of both tumor types ( Fig.  7A and B) , indicating that both tumor types depend on tumor angiogenesis. In contrast, PTK treatment had no effect on MTflECad or MTDECad cells cultured in 2D or as mammospheres ( Supplementary Fig. S5F and S5G) .
Conversely, the forced expression of VEGF-A in MTflECad cells significantly increased tumor microvessel density and reduced tumor necrosis but only moderately accelerated tumor onset ( Supplementary Fig. S6A-S6D ). The increased vasculature was not associated to diminished hypoxia and only an intermediate increase in the number of perfused vessels could be observed ( Supplementary Fig. S6E-S6H ). In these tumors, apoptosis was significantly decreased by VEGF-A expression, whereas tumor cell proliferation was unaffected ( Supplementary Fig. S6I and S6J ). The modulation of VEGF levels had no impact on the capacity or on the quality of spheroid formation ( Supplementary Fig. S5D, S5E , and S5G), indicating that VEGF-A upregulation plays a role only in the context of an EMT-induced mechanism. These results indicate that, while critical for tumor angiogenesis, VEGF-A by itself is not sufficient to efficiently promote tumor initiation. Besides VEGF-A, the other family members VEGF-B, C, and D were also found upregulated in their expression during EMT and in spheroid culture of MTflECad and MTDECad cells and tumors, yet to varying degrees and without affecting tumor lymphangiogenesis ( Supplementary Fig. S7A-S7D) . Moreover, shRNAmediated ablation of VEGF-C expression failed to affect MTDECad tumor formation ( Supplementary Fig. S7E and  S7F) . Hence, other factors were likely necessary to support VEGF-A in the tumorigenic abilities of mesenchymal MTDECad cells. High levels of matrix metalloproteinases (MMP), inflammatory cytokines, and activated endothelial cell markers were found in lysates of MTDECad tumors as Fig. S8 ). Accordingly, forced expression of VEGF-A in MTflECad cells increased, whereas VEGF-A knockdown in MTDECad cells decreased conditioned mediuminduced HUVEC proliferation. Figure 6 . Tumor cell-derived VEGF-A is required for early tumor onset. A, secreted VEGF-A protein levels were assessed by ELISA in the supernatant of MTflECad and MTDECad cells that have been infected to express either a nontargeting control shRNA (shCtr) or an shRNA against VEGF-A (shVA #1). The means of three independent measurements are plotted with SEM. Statistical significances were calculated using a paired Student t test. Ã , P < 0.05. B, two hundred MTflECad and MTDECad cells stably expressing either shRNA against VEGF-A (shVA #1) or control shRNA (shCtr) were injected into the ninth mammary fat pad of RG mice. Tumor formation was monitored by palpation. Statistical significance was evaluated by the Mann-Whitney U test. ÃÃ , P < 0.01. C and D, additional small hairpins against VEGF-A (shVA #4, shVA #5, shVA #8) were used to validate the result with shVA #1. Knockdown efficiency was tested by measuring the levels of VEGF-A in the cell supernatants by ELISA. The mean of three independent measurements is plotted AE SEM (C). Tumor onset (D) was determined as described in B. E, vascularization of MTDECad shCtr and shVA #1 tumors was analyzed by immunofluorescence staining for CD31 (green). Representative immunofluorescence microscopy pictures are shown. Scale bars, 100 mm. F and G, the degree of vascularization was quantified by counting the number of CD31-positive vessels per area (F) and the area fraction of CD31-positive vessels (G). Statistical analysis of the quantifications was performed using a Mann-Whitney U test. ÃÃÃ , P < 0.001; N ¼ 4 mice. H, MTDECad expressing a control shRNA (shCtr) or shRNAs targeting VEGF-A (shVA #1, #4, #5, #8) was cultured for two passages as spheroids (M2). After dissociation of the spheroids, 10 cells in PBS were injected into the ninth fat pad of RG mice. Tumor onset was monitored and plotted. The experiment was finally terminated 160 days after injection and mice that had not developed tumors were recorded with 160 days. Statistical analysis of the quantifications was performed using the Fisher exact test.
Ã , P < 0.05; ÃÃÃ , P < 0.001.
To investigate the possibility that VEGF-A upregulation could have implications on the CSC's intrinsic properties, we analyzed the VEGFR1 and Nrps levels in MTflECad and MTDECad in 2D or spheroids culturing, as well the effect of downregulation of Nrp1 and Nrp2 on cell proliferation and cell cycle. In contrast to what has been previously shown in other models (17), we did not observe any effect of VEGFR and Nrp expression on cell proliferation or mammosphere formation in our cellular models (data not shown).
To determine VEGF-A expression by tumorigenic CSCs of human breast tumors, we isolated bona fide CSCs from patients' primary breast tumors that have been previously serially transplanted in immunocompromised mice (18) as well as from the human breast cancer cell line MDA-MB-231. Single-cell suspensions were stained with antibodies against CD44 and CD24. CD44 
/CD24
À/low putative CSC and (19) were isolated by flow cytometry, and the expression of VEGF-A mRNA was determined by qRT-PCR. Indeed, the putative CSC population exhibited significantly higher levels of VEGF-A mRNA expression than their non-CSC counterparts ( Fig. 7C and D) , indicating that also in human breast cancer cells, increased cancer cell stemness correlated with high VEGF-A expression.
Discussion
In this report, we have utilized standardized assays for CSCs to delineate the mechanisms underlying EMT-induced cancer stemness. While spheroid growth, tumor initiation, and metastatic spread revealed a correlation between EMT and hallmarks of CSCs (shown here), the analysis of cell surface markers (Supplementary Table S1 ), aldehyde dehydrogenase-positive populations, label-retaining cells, and general drug resistance (data not shown) did not correlate with EMT. While the identification of appropriate stem cell markers for the isolation of CSCs remains challenging (13), growing evidence links tumor-initiating cells with proangiogenic signals (17, 20, 21) . Notably, we have identified VEGF-A-mediated angiogenesis as one critical determinant of the increased tumorigenicity of cells undergoing EMT: (i) VEGF-A and several other angiogenic factors and cytokines are upregulated in murine breast cancer cells during EMT, (ii) CSCs of human primary breast cancers or from a human breast cancer cell line also display increased levels of VEGF-A, (iii) VEGF-A is required for the increased tumorigenicity of cells undergoing EMT, yet (iv) VEGF by itself is not sufficient to promote tumorigenicity of epithelial cancer cells, indicating that additional angiogenic factors regulated in their expression during EMT are critical for an effective tumor initiation. Our results also show that VEGF-A is required for EMT-induced angiogenesis in the early events of tumor initiation, in line with similar results in skin and brain (17) and with an established central role for VEGF-A in tumor progression (22) (23) (24) .
As few as 10 mesenchymal cells efficiently initiated tumors upon orthotopic transplantation, while their epithelial counterparts were much less efficient. The calculated CSC frequency of MTDECad 
